Anaptys Partner Search Boosted By Phase III Skin Disease Success
After disappointments in other indications, notably hidradenitis suppurativa, AnaptysBio has posted positive Phase III results for its IL-36 receptor-targeting monoclonal antibody imsidolimab in generalized pustular psoriasis.
